{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:49:44Z","timestamp":1790808584593,"version":"4.1.0"},"reference-count":221,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.addr.2025.115678","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T15:45:53Z","timestamp":1756482353000},"page":"115678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Drug delivery, development, and technological aspects for peripheral drug eluting stents"],"prefix":"10.1016","volume":"226","author":[{"given":"Sarika A.","family":"Jadhav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur J.","family":"Raval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6803-2912","authenticated-orcid":false,"given":"Vandana B.","family":"Patravale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2025.115678_b0005","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.atherosclerosis.2018.05.033","article-title":"Update on peripheral artery disease: Epidemiology and evidence-based facts","volume":"275","author":"Shu","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2025.115678_b0010","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jvs.2022.12.015","article-title":"Mayo Smith, the global burden of peripheral artery disease","volume":"77","author":"Eid","year":"2023","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.addr.2025.115678_b0015","unstructured":"Hypertension, (n.d.). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension (accessed May 4, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0020","doi-asserted-by":"crossref","first-page":"e980","DOI":"10.1016\/S2214-109X(19)30293-1","article-title":"Differential burden of peripheral artery disease","volume":"7","author":"Kengne","year":"2019","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.addr.2025.115678_b0025","doi-asserted-by":"crossref","unstructured":"M.A. Allison D.G. Armstrong P.P. Goodney N.M. Hamburg L. Kirksey K.J. Lancaster C.I. Mena-Hurtado S. Misra D.J. Treat-Jacobson K.T. White Solaru null null, Health Disparities in Peripheral Artery Disease: a Scientific Statement from the American Heart Association, Circulation 148 2023 10.1161\/CIR.0000000000001153 286 296.","DOI":"10.1161\/CIR.0000000000001153"},{"key":"10.1016\/j.addr.2025.115678_b0030","doi-asserted-by":"crossref","first-page":"16812","DOI":"10.1002\/jcp.28350","article-title":"A review on coronary artery disease, its risk factors, and therapeutics","volume":"234","author":"Malakar","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.addr.2025.115678_b0035","first-page":"307","article-title":"Pathophysiology of superficial femoral artery in-stent restenosis","volume":"55","author":"Yahagi","year":"2014","journal-title":"J. Cardiovasc. Surg. (Torino)"},{"key":"10.1016\/j.addr.2025.115678_b0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/vhrm.1.1.73.58932","article-title":"Restenosis after Percutaneous Angioplasty: the Role of Vascular Inflammation","volume":"1","author":"Schillinger","year":"2005","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.addr.2025.115678_b0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2005.09.042","article-title":"Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries","volume":"524","author":"Parry","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.addr.2025.115678_b0050","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jacc.2016.11.055","article-title":"10-Year Clinical Outcome after Randomization to Treatment by Sirolimus-or Paclitaxel-Eluting CoronaryStents","volume":"69","author":"Gall\u00f8e","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2025.115678_b0055","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/eurheartj\/ehy193","article-title":"The world\u2019s first 2 coronary angioplasty patients","volume":"39","author":"Meier","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2025.115678_b0060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcin.2013.04.011","volume":"6","author":"Serruys","year":"2013","journal-title":"J. Am. Coll. Cardiol. Intv."},{"key":"10.1016\/j.addr.2025.115678_b0065","unstructured":"EspritTM BTK Everolimus Eluting Resorbable stent.pdf, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0070","series-title":"Femoral Artery, Drug Eluting","author":"ELUVIATM, Superficial,","year":"2018"},{"key":"10.1016\/j.addr.2025.115678_b0075","author":"Zilver\u00ae, PTX\u00ae Drug-Eluting,","year":"2011","journal-title":"Peripheral Stent, Cook Incorporated"},{"key":"10.1016\/j.addr.2025.115678_b0080","unstructured":"Medical Device Sterilization Town Hall: Sterilization Method Selection for New and Existing Devices - 05\/23\/2024, FDA (2024). https:\/\/www.fda.gov\/medical-devices\/medical-devices-news-and-events\/medical-device-sterilization-town-hall-sterilization-method-selection-new-and-existing-devices (accessed May 4, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0085","unstructured":"C. for D. and R. Health, Sterilization for Medical Devices, FDA (2024). https:\/\/www.fda.gov\/medical-devices\/general-hospital-devices-and-supplies\/sterilization-medical-devices (accessed May 4, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0090","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jvs.2013.03.052","article-title":"Design considerations for studies of the biomechanical environment of the femoropopliteal arteries","volume":"58","author":"Ansari","year":"2013","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.addr.2025.115678_b0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10237-017-0953-z","article-title":"Effect of aging on mechanical stresses, deformations, and hemodynamics in human femoropopliteal artery due to limb flexion","volume":"17","author":"Desyatova","year":"2018","journal-title":"Biomech. Model. Mechanobiol."},{"key":"10.1016\/j.addr.2025.115678_b0100","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2017.0025","article-title":"Limb flexion-induced twist and associated intramural stresses in the human femoropopliteal artery","volume":"14","author":"Desyatova","year":"2017","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.addr.2025.115678_b0105","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.jbiomech.2014.04.053","article-title":"Three-dimensional bending, torsion and axial compression of the femoropopliteal artery during limb flexion","volume":"47","author":"MacTaggart","year":"2014","journal-title":"J. Biomech."},{"key":"10.1016\/j.addr.2025.115678_b0110","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jvs.2017.01.071","article-title":"Limb flexion-induced axial compression and bending in human femoropopliteal artery segments","volume":"67","author":"Poulson","year":"2018","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.addr.2025.115678_b0115","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1063\/1.1729603","article-title":"Effect of Low\u2010Temperature phase changes on the Mechanical Properties of Alloys near Composition TiNi","volume":"34","author":"Buehler","year":"1963","journal-title":"J. Appl. Phys."},{"key":"10.1016\/j.addr.2025.115678_b0120","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s10439-018-1990-1","article-title":"Nitinol Stents in the Femoropopliteal Artery: a Mechanical Perspective on Material, Design, and Performance","volume":"46","author":"Maleckis","year":"2018","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.addr.2025.115678_b0125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jmbbm.2017.07.017","article-title":"Comparison of femoropopliteal artery stents under axial and radial compression, axial tension, bending, and torsion deformations","volume":"75","author":"Maleckis","year":"2017","journal-title":"J. Mech. Behav. Biomed. Mater."},{"key":"10.1016\/j.addr.2025.115678_b0130","first-page":"642","article-title":"Reduction of Atherothrombosis for continued Health (REACH) Registry investigators","volume":"3","author":"Mahoney","year":"2010","journal-title":"Vascular Hospitalization Rates and Costs in Patients with Peripheral Artery Disease in the United States, Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.addr.2025.115678_b0135","doi-asserted-by":"crossref","unstructured":"M.R. Chase, H.S. Friedman, P. Navaratnam, K. Heithoff, R.J. Simpson, Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States, J Manag Care Spec Pharm 22 (2016) 667\u2013675. 10.18553\/jmcp.2016.15010.","DOI":"10.18553\/jmcp.2016.15010"},{"key":"10.1016\/j.addr.2025.115678_b0140","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.atherosclerosis.2019.05.026","article-title":"Cost and inpatient burden of peripheral artery disease: Findings from the National Inpatient Sample","volume":"286","author":"Kohn","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.addr.2025.115678_b0145","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.pmatsci.2011.11.001","article-title":"Manufacturing and processing of NiTi implants: a review","volume":"57","author":"Elahinia","year":"2012","journal-title":"Prog. Mater Sci."},{"key":"10.1016\/j.addr.2025.115678_b0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0921-5093(99)00294-4","article-title":"An overview of nitinol medical applications","volume":"273\u2013275","author":"Duerig","year":"1999","journal-title":"Mater. Sci. Eng. A"},{"key":"10.1016\/j.addr.2025.115678_b0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/13645700009063056","article-title":"Biocompatibility of Nitinol","volume":"9","author":"Ryh\u00e4nen","year":"2000","journal-title":"Minim. Invasive Ther. Allied Technol."},{"key":"10.1016\/j.addr.2025.115678_b0160","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0142-9612(00)00371-9","article-title":"Self-expandable chitosan stent: design and preparation","volume":"22","author":"Lauto","year":"2001","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2025.115678_b0165","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.biomaterials.2006.11.020","article-title":"The short-term effects on restenosis and thrombosis of echinomycin-eluting stents topcoated with a hydrophobic heparin-containing polymer","volume":"28","author":"Lee","year":"2007","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2025.115678_b0170","unstructured":"C. for D. and R. Health, UPDATE: Paclitaxel-Coated Devices to Treat Peripheral Arterial Disease Unlikely to Increase Risk of Mortality - Letter to Health Care Providers, FDA (2023). https:\/\/www.fda.gov\/medical-devices\/letters-health-care-providers\/update-paclitaxel-coated-devices-treat-peripheral-arterial-disease-unlikely-increase-risk-mortality (accessed May 6, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0175","unstructured":"C. for D. and R. Health, Paclitaxel-Coated Balloons and Stents for Peripheral Arterial Disease, FDA (2023). https:\/\/www.fda.gov\/medical-devices\/cardiovascular-devices\/paclitaxel-coated-balloons-and-stents-peripheral-arterial-disease (accessed May 7, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0180","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1016\/j.jcin.2019.08.025","article-title":"Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease","volume":"12","author":"Ouriel","year":"2019","journal-title":"J. Am. Coll. Cardiol. Intv."},{"key":"10.1016\/j.addr.2025.115678_b0185","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011245","article-title":"Risk of death following Application of Paclitaxel\u2010Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: a Systematic Review and Meta\u2010Analysis of Randomized Controlled Trials","volume":"7","author":"Katsanos","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.addr.2025.115678_b0190","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1093\/eurheartj\/ehz698","article-title":"Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis","volume":"41","author":"Freisinger","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.addr.2025.115678_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-021-05631-9","article-title":"Head-to-head comparison of sirolimus- versus paclitaxel-coated balloon angioplasty in the femoropopliteal artery: study protocol for the randomized controlled SIRONA trial","volume":"22","author":"Teichgr\u00e4ber","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.addr.2025.115678_b0200","unstructured":"CID - Carbostent & Implantable Devices, Innovative siroLimus seLf Expanding drUg-eluting Stent for the treatMent of perIpheral Disease: Evaluation of Safety aNd efficAcy. The ILLUMINA Study. (ILLUMINA), clinicaltrials.gov, 2021. https:\/\/clinicaltrials.gov\/study\/NCT03510676 (accessed May 4, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0205","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jvs.2022.09.022","article-title":"A systematic review and meta-analysis of sirolimus-eluting stents for treatment of below-the-knee arterial disease","volume":"77","author":"Fong","year":"2023","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.addr.2025.115678_b0210","unstructured":"Esprit BTK Resorbable Scaffold System | Abbott, (n.d.). https:\/\/www.cardiovascular.abbott\/us\/en\/hcp\/products\/peripheral-intervention\/esprit-btk-resorbable-scaffold-system.html (accessed May 1, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0215","series-title":"Handbook of Biodegradable Polymers","article-title":"Applications of Biodegradable Polymers in Coronary Stents and Cardiac Tissue Engineering","author":"Jadhav","year":"2024"},{"key":"10.1016\/j.addr.2025.115678_b0220","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00270-023-03652-2","article-title":"Treatment of Femoropopliteal Artery Disease with Polymer-Coated Drug-Eluting Stent: 5-Year results of a prospective, Non-Randomized Study Including the Halo Phenomenon","volume":"47","author":"Torsello","year":"2024","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.addr.2025.115678_b0225","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00270-020-02693-1","article-title":"Two-Year Efficacy and Safety results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent","volume":"44","author":"M\u00fcller-H\u00fclsbeck","year":"2021","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.addr.2025.115678_b0230","unstructured":"Eluvia Drug-Eluting Stent, Www.Bostonscientific.Com (n.d.). https:\/\/www.bostonscientific.com\/en-EU\/medical-specialties\/vascular-surgery\/drug-eluting-stent-drug-coated-balloon\/eluvia.html (accessed May 4, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0235","unstructured":"Dake MD, Ansel GM, Jaff MR, et al., Unrivaled Long-term data_Zilver PTX, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0240","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jvir.2021.02.014","article-title":"Vascular Response of a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) versus a Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) in healthy Swine Femoropopliteal arteries","volume":"32","author":"Sakamoto","year":"2021","journal-title":"J. Vasc. Interv. Radiol."},{"key":"10.1016\/j.addr.2025.115678_b0245","unstructured":"EverFlexTM Self- Expanding Peripheral Stent System.pdf, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0250","unstructured":"BioMimics 3D Vascular Stent 2018.pdf, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0255","unstructured":"LifeStreamTM Balloon Expandable Vascular Covered Stent.pdf, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0260","unstructured":"The Bard\u00ae LifeStent\u00ae Vascular Stent System 2016.pdf, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0265","volume":"n.d","author":"Supera\u00ae Peripheral Stent,","year":"2014","journal-title":"System"},{"key":"10.1016\/j.addr.2025.115678_b0270","unstructured":"Biotyx Medical (Shenzhen) Co., Ltd., A Prospective, Multicentre, Single Arm Clinical Trial to Assess the Safety and Effectiveness of Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS TitanTM) in Treating Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease, clinicaltrials.gov, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05971394 (accessed August 15, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0275","unstructured":"Tack Endovascular System\u00ae 2019.pdf, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0280","unstructured":"C. for D. and R. Health, Endovascular System Recall: Philips Removes and Discontinues Distribution of Tack Endovascular System Due to User Challenges That Caused Additional Procedures to Reposition or Remove Implant, FDA (2025). https:\/\/www.fda.gov\/medical-devices\/medical-device-recalls\/endovascular-system-recall-philips-removes-and-discontinues-distribution-tack-endovascular-system (accessed April 11, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0285","unstructured":"S.M.A.R.T.TM Nitinol Stent and S.M.A.R.T.TM CONTROL Nitinol Stent System.pdf, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0290","unstructured":"Class 2 Device Recall Vascular Stent System, (n.d.). https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfres\/res.cfm?id=212827 (accessed April 19, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0295","unstructured":"Clinical investigation of the Qmedics EXIST NiTi Stent type Flex & Pull in adults with Peripheral Artery Disease (PAD) (of the Q-medics NiTi Stent Family_.pdf, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0300","unstructured":"Biotyx Medical (Shenzhen) Co., Ltd., A Prospective, Multicentre, Single Arm Clinical Trial to Assess the Safety and Effectiveness of Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS TitanTM) in Treating Patients With Infrapopliteal Arterial Stenosis or Occlusive Disease, clinicaltrials.gov, 2023. https:\/\/clinicaltrials.gov\/study\/NCT05971394 (accessed April 21, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0305","unstructured":"ZENFLEX | List Results | ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/search?term=ZENFLEX (accessed April 21, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0310","unstructured":"Terumo Medical Corporation, A Multi-center Clinical Trial of the MisagoTM Self-Expanding Stent System for Superficial Femoral Artery, clinicaltrials.gov, 2017. https:\/\/clinicaltrials.gov\/study\/NCT01118117 (accessed April 21, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0315","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1021\/js980021f","article-title":"Arterial uptake of biodegradable nanoparticles: effect of surface modifications","volume":"87","author":"Labhasetwar","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.addr.2025.115678_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120403","article-title":"Bivalirudin and sirolimus co-eluting coronary stent: potential strategy for the prevention of stent thrombosis and restenosis","author":"Sane","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2025.115678_b0325","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41427-018-0064-z","article-title":"Design and testing of hydrophobic core\/hydrophilic shell nano\/micro particles for drug-eluting stent coating","volume":"10","author":"Du","year":"2018","journal-title":"NPG Asia Mater."},{"key":"10.1016\/j.addr.2025.115678_b0330","article-title":"Nanoparticles eluting stents for coronary intervention: Formulation, characterization and in vitro evaluation","author":"Agrawal","year":"2021","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.addr.2025.115678_b0335","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(17)33103-3","article-title":"A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial","volume":"391","author":"De Winter","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2025.115678_b0340","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1021\/acsnano.5b00651","article-title":"Bioresorbable Electronic Stent Integrated with Therapeutic Nanoparticles for Endovascular Diseases","volume":"9","author":"Son","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2025.115678_b0345","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1166\/jbn.2014.1856","article-title":"Improved Biocompatibility of Poly(lactic-co-glycolic acid) and Poly-L-Lactic Acid Blended with Nanoparticulate Amorphous Calcium Phosphate in Vascular Stent applications","volume":"10","author":"Zheng","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.addr.2025.115678_b0350","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201800644","article-title":"Nanoparticles for Detection and Treatment of Peripheral Arterial Disease","volume":"14","author":"Noukeu","year":"2018","journal-title":"Small"},{"key":"10.1016\/j.addr.2025.115678_b0355","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1021\/nn507269g","article-title":"Nanoscale strategies: Treatment for Peripheral Vascular Disease and critical Limb Ischemia","volume":"9","author":"Tu","year":"2015","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2025.115678_b0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268307","article-title":"Nanoparticle coatings for controlled release of quercetin from an angioplasty balloon","volume":"17","author":"Craciun","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2025.115678_b0365","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.1038\/s41598-017-08441-9","article-title":"Hybrid Nitric Oxide Donor and its Carrier for the Treatment of Peripheral Arterial Diseases","volume":"7","author":"Le","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115678_b0370","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2012.01.008","article-title":"Novel nanocomposite stent coating releasing resveratrol and quercetin reduces neointimal hyperplasia and promotes re-endothelialization","volume":"159","author":"Kleinedler","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115678_b0375","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/jbm.b.31894","article-title":"Synergistic effect of resveratrol and quercetin released from drug-eluting polymer coatings for endovascular devices","volume":"99","author":"Kleinedler","year":"2011","journal-title":"J. Biomed. Mater. Res. B Appl. Biomater."},{"key":"10.1016\/j.addr.2025.115678_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsusc.2023.156410","article-title":"Rapamycin-loaded nanocoating to specially modulate smooth muscle cells on ZE21B alloy for vascular stent application","volume":"615","author":"Wang","year":"2023","journal-title":"Appl. Surf. Sci."},{"key":"10.1016\/j.addr.2025.115678_b0385","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2019.12.031","article-title":"Adventitial injection delivery of nano-encapsulated sirolimus (Nanolimus) to injury-induced porcine femoral vessels to reduce luminal restenosis","volume":"319","author":"Ang","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115678_b0390","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3109\/13880209.2013.871640","article-title":"Fusogenic pH sensitive liposomal formulation for rapamycin: improvement of antiproliferative effect","volume":"52","author":"Ghanbarzadeh","year":"2014","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.addr.2025.115678_b0395","article-title":"A drug repurposing approach of Atorvastatin calcium for its antiproliferative activity for effective treatment of breast cancer: In vitro and in vivo assessment","volume":"7","author":"Gaber","year":"2024","journal-title":"International Journal of Pharmaceutics: X"},{"key":"10.1016\/j.addr.2025.115678_b0400","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.colsurfb.2013.12.024","article-title":"Improvement of the antiproliferative effect of Rapamycin on tumor cell lines by poly (monomethylitaconate)-based pH-sensitive, plasma stable liposomes","volume":"115","author":"Ghanbarzadeh","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.addr.2025.115678_b0405","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3109\/08982100902963043","article-title":"Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells","volume":"19","author":"Rouf","year":"2009","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.addr.2025.115678_b0410","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1039\/D3TB02643D","article-title":"Microneedle-assisted percutaneous delivery of methotrexate-loaded nanoparticles enabling sustained anti-inflammatory effects in psoriasis therapy","volume":"12","author":"Du","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2025.115678_b0415","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijpharm.2011.04.055","article-title":"Use of remote film loading methodology to entrap sirolimus into liposomes: Preparation, characterization and in vivo efficacy for treatment of restenosis","volume":"414","author":"Haeri","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2025.115678_b0420","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s13346-023-01390-z","article-title":"Sirolimus-loaded exosomes as a promising vascular delivery system for the prevention of post-angioplasty restenosis","volume":"14","author":"Mehryab","year":"2024","journal-title":"Drug Deliv. and Transl. Res."},{"key":"10.1016\/j.addr.2025.115678_b0425","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijpharm.2013.07.003","article-title":"Sirolimus-loaded stealth colloidal systems attenuate neointimal hyperplasia after balloon injury: a comparison of phospholipid micelles and liposomes","volume":"455","author":"Haeri","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2025.115678_b0430","doi-asserted-by":"crossref","first-page":"43552","DOI":"10.1039\/C5RA04057D","article-title":"Immunosuppressive nano-therapeutic micelles downregulate endothelial cell inflammation and immunogenicity","volume":"5","author":"Nadig","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.addr.2025.115678_b0435","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.exer.2014.02.001","article-title":"Cholesterol-poly(ethylene) glycol nanocarriers for the transscleral delivery of sirolimus","volume":"121","author":"Elsaid","year":"2014","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.addr.2025.115678_b0440","doi-asserted-by":"crossref","first-page":"8105","DOI":"10.1167\/iovs.12-10717","article-title":"Positively charged amphiphilic chitosan derivative for the transscleral delivery of rapamycin","volume":"53","author":"Elsaid","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.addr.2025.115678_b0445","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/10717540802481307","article-title":"New approach for local delivery of rapamycin by bioadhesive PLGA-carbopol nanoparticles","volume":"16","author":"Zou","year":"2009","journal-title":"Drug Deliv."},{"key":"10.1016\/j.addr.2025.115678_b0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2024.134794","article-title":"Antiproliferative activity in metastatic breast cancer cells of nanoparticles containing a novel indole-thiazole derivative","author":"Soares","year":"2024","journal-title":"Colloids and Surfaces a: Physicochemical and Engineering Aspects 700"},{"key":"10.1016\/j.addr.2025.115678_b0455","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jconrel.2006.05.021","article-title":"Release of anti-restenosis drugs from poly(ethylene oxide)-poly(dl-lactic-co-glycolic acid) nanoparticles","volume":"114","author":"Zweers","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115678_b0460","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.1039\/D4TB00615A","article-title":"pH-sensitive doxorubicin delivery using zinc oxide nanoparticles as a rectified theranostic platform: in vitro anti-proliferative, apoptotic, cell cycle arrest and in vivo radio-distribution studies","volume":"12","author":"Swidan","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.addr.2025.115678_b0465","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2016.05.049","article-title":"Sustained delivery by a cyclodextrin material-based nanocarrier potentiates antiatherosclerotic activity of rapamycin via selectively inhibiting mTORC1 in mice","volume":"235","author":"Dou","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115678_b0470","unstructured":"Advanced NanoTherapies - Next Generation Drug-Coated Balloons, Advanced NanoTherapies (n.d.). https:\/\/advancednanotherapies.com\/ (accessed May 4, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0475","unstructured":"MagicTouch: Sirolimus Drug Coated Balloon Catheter, Concept Medical (n.d.). https:\/\/www.conceptmedical.com\/product\/magic-touch\/ (accessed May 4, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0480","unstructured":"SELUTION SLR PTA Drug Eluting Balloon, Cordis (n.d.). https:\/\/cordis.com\/emea\/products\/peripheral-interventions\/lower-extremities\/selution-slr-drug-eluting-pta-balloon\/selution-slr-pta-drug-eluting-balloon (accessed May 4, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0485","unstructured":"Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon | Orchestra BioMed, (n.d.). https:\/\/investors.orchestrabiomed.com\/news-releases\/news-release-details\/orchestra-biomed-receives-fda-approval-ide-initiate-us-coronary\/ (accessed May 4, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0490","unstructured":"IN.PACTTM Medtronic, (n.d.). https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf14\/P140010S037C.pdf (accessed January 29, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0495","unstructured":"RangerTM, (n.d.). https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf19\/P190019D.pdf (accessed January 29, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0500","unstructured":"LUTONIX\u00ae, (n.d.). https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf17\/P170003B.pdf (accessed January 29, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0505","unstructured":"AGENTTM Paclitaxel-Coated Balloon Catheter, (n.d.). https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf23\/P230035B.pdf (accessed January 29, 2025)."},{"issue":"44\u201346","key":"10.1016\/j.addr.2025.115678_b0510","first-page":"48","article-title":"Using ultrasonic spray nozzles to coat drug-eluting stents","volume":"17","author":"Berger","year":"2006","journal-title":"Med. Device Technol."},{"key":"10.1016\/j.addr.2025.115678_b0515","series-title":"7th Asian-Pacific Conference on Medical and Biological Engineering","first-page":"70","article-title":"Coating preparation and drug delayed release of dexamethasone-eluting intravascular stents in vitro and in vivo","author":"Chen","year":"2008"},{"key":"10.1016\/j.addr.2025.115678_b0520","first-page":"277","article-title":"Formulation of Nanoparticle-Eluting Stents by a Cationic Electrodeposition Coating Technology: Efficient Nano-Drug delivery via Bioabsorbable Polymeric Nanoparticle-Eluting Stents in Porcine Coronary arteries","author":"Nakano","year":"2009","journal-title":"JACC: Cardiovascular Interventions 2"},{"issue":"1","key":"10.1016\/j.addr.2025.115678_b0525","first-page":"13","volume":"1","author":"Joung","year":"2014","journal-title":"Precise Ultrasonic Coating and Controlled Release of Sirolimus with Biodegradable Polymers for Drug-Eluting Stent"},{"key":"10.1016\/j.addr.2025.115678_b0530","unstructured":"H.L. Berger, S.-T. Corporation, Coating Drug-eluting Arterial Stents Using Ultrasonic Spray Nozzles, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0535","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.actbio.2019.06.008","article-title":"An electrospun fiber-covered stent with programmable dual drug release for endothelialization acceleration and lumen stenosis prevention","volume":"94","author":"Zhang","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2025.115678_b0540","doi-asserted-by":"crossref","first-page":"9539","DOI":"10.1021\/ie102163z","article-title":"Mechanism and in Vitro Release Kinetic Study of Sirolimus from a Biodegradable Polymeric Matrix Coated Cardiovascular Stent","volume":"50","author":"Raval","year":"2011","journal-title":"Ind. Eng. Chem. Res."},{"key":"10.1016\/j.addr.2025.115678_b0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2024.105629","article-title":"Sirolimus micro\/nano particles coated drug-eluting stents using QbD paradigm: potential approach for the amelioration of arterial diseases","volume":"95","author":"Jadhav","year":"2024","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.addr.2025.115678_b0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124572","article-title":"In vitro drug release profiling of Sirolimus polymeric microparticles coated long-acting stents","author":"Jadhav","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2025.115678_b0555","first-page":"941","article-title":"High-Frequency Ultrasonic Atomization with Pulsed Excitation","author":"Lozano","year":"2004","journal-title":"Journal of Fluids Engineering 125"},{"key":"10.1016\/j.addr.2025.115678_b0560","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1121\/1.1909020","article-title":"Ultrasonic Atomization of Liquids","volume":"34","author":"Lang","year":"1962","journal-title":"J. Acoust. Soc. Am."},{"key":"10.1016\/j.addr.2025.115678_b0565","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1208\/s12249-014-0266-9","article-title":"Application of Quality by Design (QbD) Approach to Ultrasonic Atomization Spray Coating of Drug-Eluting Stents","volume":"16","author":"McDermott","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2025.115678_b0570","doi-asserted-by":"crossref","first-page":"6911","DOI":"10.1021\/la4010246","article-title":"Process optimization of ultrasonic spray coating of polymer films","volume":"29","author":"Bose","year":"2013","journal-title":"Langmuir"},{"key":"10.1016\/j.addr.2025.115678_b0575","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1007\/s11431-011-4580-0","article-title":"Study on ultrasonic spray technology for the coating of vascular stent","volume":"54","author":"Yi","year":"2011","journal-title":"Sci. China Technol. Sci."},{"key":"10.1016\/j.addr.2025.115678_b0580","volume":"20","author":"Bentley","year":"2008","journal-title":"The Problem with Stents"},{"key":"10.1016\/j.addr.2025.115678_b0585","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1208\/s12249-011-9644-8","article-title":"Radiation and Ethylene Oxide Terminal Sterilization Experiences with Drug Eluting Stent Products","volume":"12","author":"Lambert","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2025.115678_b0590","doi-asserted-by":"crossref","first-page":"A82","DOI":"10.1016\/j.ajic.2023.01.020","article-title":"Sterilization of 20 billion medical devices by ethylene oxide (ETO): Consequences of ETO closures and alternative sterilization technologies\/solutions","volume":"51","author":"Rutala","year":"2023","journal-title":"Am. J. Infect. Control"},{"key":"10.1016\/j.addr.2025.115678_b0595","unstructured":"O. of the Commissioner, Statement on concerns with medical device availability due to certain sterilization facility closures, FDA (2020). https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-concerns-medical-device-availability-due-certain-sterilization-facility-closures (accessed May 4, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0600","unstructured":"Center for Devices and Radiological Health Radiation Sterilization Master File Pilot FDA.pdf, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0605","unstructured":"Sterilization of health care products Radiation: British Standard, (n.d.). https:\/\/www.ipen.br\/biblioteca\/slr\/normas\/N2958 (accessed May 13, 2024)."},{"key":"10.1016\/j.addr.2025.115678_b0610","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1021\/ed058p168","article-title":"Radiation processing: the industrial applications of radiation chemistry","volume":"58","author":"Silverman","year":"1981","journal-title":"J. Chem. Educ."},{"key":"10.1016\/j.addr.2025.115678_b0615","unstructured":"GIPA-WP-GIPA-iia-Sterilization-Modalities-FINAL-Version-2017-October-308772.pdf, (n.d.). https:\/\/gipalliance.net\/wp-content\/uploads\/2013\/01\/GIPA-WP-GIPA-iia-Sterilization-Modalities-FINAL-Version-2017-October-308772.pdf (accessed May 18, 2024)."},{"key":"10.1016\/j.addr.2025.115678_b0620","unstructured":"C. for D. and R. Health, Quality Management System Regulation: Final Rule Amending the Quality System Regulation \u2013 Frequently Asked Questions, FDA (2025). https:\/\/www.fda.gov\/medical-devices\/quality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\/quality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked (accessed April 19, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0625","unstructured":"H.F. Program, Food Irradiation: What You Need to Know, FDA (2025). https:\/\/www.fda.gov\/food\/buy-store-serve-safe-food\/food-irradiation-what-you-need-know (accessed April 19, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0630","unstructured":"E-Beam Sterilization Technology | E-BEAM Services, Electron Beam Sterilization | Polymer Modification | Crosslinking | E-BEAM Services (n.d.). https:\/\/ebeamservices.com\/e-beam-sterilization\/ (accessed April 19, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0635","unstructured":"CDC, Disinfection and Sterilization Guideline, Infection Control (2024). https:\/\/www.cdc.gov\/infection-control\/hcp\/disinfection-and-sterilization\/index.html (accessed May 6, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0640","unstructured":"CDC, Ethylene Oxide \u201cGas\u201d Sterilization, Infection Control (2024). https:\/\/www.cdc.gov\/infection-control\/hcp\/disinfection-sterilization\/ethylene-oxide-sterilization.html (accessed May 6, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0645","unstructured":"SYNERGYTM Everolimus-Eluting Platinum Chromium Coronary Stent System, (n.d.). https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf15\/P150003b.pdf (accessed May 18, 2024)."},{"key":"10.1016\/j.addr.2025.115678_b0650","unstructured":"xIENCE STENT.pdf, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0655","unstructured":"Supraflex Cruz TZIFUWEN REV 08 Single.pdf, (n.d.). https:\/\/www.smtpl.com\/sites\/default\/files\/2021-09\/Supraflex%20Cruz%20TZIFUWEN%20REV%2008%20Single.pdf (accessed May 18, 2024)."},{"key":"10.1016\/j.addr.2025.115678_b0660","doi-asserted-by":"crossref","DOI":"10.2147\/VHRM.S200699","article-title":"Real-World Use of Ultrathin-Strut Biodegradable Polymer-Coated Sirolimus-Eluting Stents In patients with Coronary Artery Disease: 6-month Clinical Outcomes","volume":"15","author":"Ajmera","year":"2019","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.addr.2025.115678_b0665","unstructured":"Tetrilimus | SMT, (n.d.). https:\/\/www.smtpl.com\/products\/tetrilimus (accessed May 18, 2024)."},{"key":"10.1016\/j.addr.2025.115678_b0670","unstructured":"A. Hawthorn, Guidance for Industry and FDA Staff: Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Asso, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0675","unstructured":"21 CFR Part 58 -- Good Laboratory Practice for Nonclinical Laboratory Studies, (n.d.). https:\/\/www.ecfr.gov\/current\/title-21\/part-58 (accessed May 18, 2024)."},{"key":"10.1016\/j.addr.2025.115678_b0680","first-page":"2018","volume":"10993\u20131","author":"Iso","year":"2025","journal-title":"(en), Biological Evaluation of Medical Devices \u2014 Part 1: Evaluation and Testing within a Risk Management Process, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0685","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(18)32262-1","article-title":"A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial","volume":"392","author":"Gray","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.addr.2025.115678_b0690","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jvs.2011.01.047","article-title":"First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease","volume":"54","author":"Lammer","year":"2011","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.addr.2025.115678_b0695","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1583\/05-1704.1","article-title":"Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial","volume":"13","author":"Duda","year":"2006","journal-title":"J. Endovasc. Ther."},{"key":"10.1016\/j.addr.2025.115678_b0700","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/01.CIR.0000029746.10018.36","article-title":"Sirolimus-Eluting Stents for the Treatment of Obstructive Superficial Femoral Artery Disease","volume":"106","author":"Duda","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2025.115678_b0705","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.RVI.0000151260.74519.CA","article-title":"Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial","volume":"16","author":"Duda","year":"2005","journal-title":"J. Vasc. Interv. Radiol."},{"key":"10.1016\/j.addr.2025.115678_b0710","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.116.022039","article-title":"Drug-Eluting Stents in the Superficial Femoral Artery","volume":"133","author":"Laird","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.addr.2025.115678_b0715","doi-asserted-by":"crossref","unstructured":"G. Massaro, V. Maffi, D. Russo, D. Benedetto, M. Bonanni, G. Chiricolo, G. Sangiorgi, \u2018Leave Nothing Behind\u2019 Strategy in Coronary and Peripheral Artery Disease: An Insight into Sirolimus-Coated Balloons, EMJ 10 (2022) 60\u201371. 10.33590\/emjintcardiol\/22-00078.","DOI":"10.33590\/emjintcardiol\/22-00078"},{"key":"10.1016\/j.addr.2025.115678_b0720","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.addr.2016.03.010","article-title":"Poly(lactic acid)\u2014Mass production, processing, industrial applications, and end of life","volume":"107","author":"Castro-Aguirre","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2025.115678_b0725","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/17434440.2021.1904894","article-title":"Current perspectives on bioresorbable scaffolds in coronary intervention and other fields","volume":"18","author":"Wu","year":"2021","journal-title":"Expert Rev. Med. Devices"},{"key":"10.1016\/j.addr.2025.115678_b0730","first-page":"1959","article-title":"Experience with Biodegradable Polymer Coated Sirolimus-Eluting Coronary Stent System in \u201cReal-Life\u201d Percutaneous Coronary intervention: 24-month Data from the Manipal-S Registry","volume":"7","author":"Shetty","year":"2013","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.addr.2025.115678_b0735","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41569-018-0124-7","article-title":"Fully bioresorbable vascular scaffolds: lessons learned and future directions","volume":"16","author":"Jinnouchi","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.addr.2025.115678_b0740","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/1526602817698935","article-title":"Lessons Learned Regarding Handling and Deployment of the Absorb Bioresorbable Vascular Scaffold in Infrapopliteal arteries","volume":"24","author":"Varcoe","year":"2017","journal-title":"J. Endovasc. Ther."},{"key":"10.1016\/j.addr.2025.115678_b0745","unstructured":"J. Abraham, ICH HARMONISED TRIPARTITE GUIDELINE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS: CHEMICAL SUBSTANCES Q6A, in: C. Tietje, A. Brouder (Eds.), Handbook of Transnational Economic Governance Regimes, Brill | Nijhoff, 2010: pp. 1041\u20131053. 10.1163\/ej.9789004163300.i-1081.897."},{"key":"10.1016\/j.addr.2025.115678_b0750","unstructured":"FDA Guidence on Coronary Drug-Eluting StentsNonclinical and Clinical Studies, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0755","unstructured":"USP 905_UNIFORMITY OF DOSAGE UNITS, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0760","unstructured":"ICH HARMONISED GUIDELINE IMPURITIES: GUIDELINE FOR RESIDUAL SOLVENTS Q3C(R9), (n.d.). https:\/\/database.ich.org\/sites\/default\/files\/ICH_Q3C%28R9%29_Guideline_MinorRevision_2024_2024_Approved.pdf (accessed May 8, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0765","unstructured":"J. Abraham, ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG PRODUCTS Q3B(R2), in: C. Tietje, A. Brouder (Eds.), Handbook of Transnational Economic Governance Regimes, Brill | Nijhoff, 2010: pp. 1041\u20131053. 10.1163\/ej.9789004163300.i-1081.897."},{"key":"10.1016\/j.addr.2025.115678_b0770","unstructured":"J. Abraham, ICH HARMONISED TRIPARTITE GUIDELINE IMPURITIES IN NEW DRUG SUBSTANCES Q3A(R2), in: C. Tietje, A. Brouder (Eds.), Handbook of Transnational Economic Governance Regimes, Brill | Nijhoff, 2010: pp. 1041\u20131053. 10.1163\/ej.9789004163300.i-1081.897."},{"key":"10.1016\/j.addr.2025.115678_b0775","unstructured":"GUIDELINE FOR ELEMENTAL IMPURITIES Q3D(R2), (n.d.). https:\/\/database.ich.org\/sites\/default\/files\/Q3D-R2_Guideline_Step4_2022_0308.pdf (accessed May 8, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b0780","unstructured":"USP 85_BACTERIAL ENDOTOXINS TEST, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0785","unstructured":"USP 788_Particulate Matter in Injections, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0790","unstructured":"USP 71 STERILITY TESTS (1).pdf, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b0795","unstructured":"U.S.P. Nf Vitro Release Test Methods for Parenteral Drug Preparations 10.31003\/USPNF_M5433_02_01 1001."},{"key":"10.1016\/j.addr.2025.115678_b0800","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.2042-7158.2011.01439.x","article-title":"In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing","volume":"64","author":"Seidlitz","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2025.115678_b0805","doi-asserted-by":"crossref","unstructured":"V.P. Shah, J. DeMuth, D.G. Hunt, Performance Test for Parenteral Dosage Forms, Dissolution Technol. 22 (2015) 16\u201321. 10.14227\/DT220415P16.","DOI":"10.14227\/DT220415P16"},{"key":"10.1016\/j.addr.2025.115678_b0810","doi-asserted-by":"crossref","unstructured":"A. Seidlitz, S. Nagel, B. Semmling, N. Grabow, K. Sternberg, W. Weitschies, Biorelevant Dissolution Testing of Drug-Eluting Stents: Experiences with a Modified Flow-Through Cell Setup, Dissolution Technol. 18 (2011) 26\u201335. 10.14227\/DT180411P26.","DOI":"10.14227\/DT180411P26"},{"key":"10.1016\/j.addr.2025.115678_b0815","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ejpb.2015.04.016","article-title":"In vitro study of sirolimus release from a drug-eluting stent: Comparison of the release profiles obtained using different test setups","volume":"93","author":"Seidlitz","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2025.115678_b0820","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s11094-019-01943-y","article-title":"In Vitro Evaluation of Drug Content in and Drug Release Kinetics from Stents with Different Types of Polymer Coating","volume":"52","author":"Prostyakova","year":"2019","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.addr.2025.115678_b0825","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s10439-018-02176-y","article-title":"Flow-Mediated Drug Transport from Drug-Eluting Stents is Negligible: Numerical and In-vitro Investigations","volume":"47","author":"Vijayaratnam","year":"2019","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.addr.2025.115678_b0830","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1021\/acsbiomaterials.9b00303","article-title":"Development of dual Drug Eluting Cardiovascular Stent with Ultrathin Flexible Poly(l-lactide-co-caprolactone) Coating","volume":"5","author":"Roopmani","year":"2019","journal-title":"ACS Biomater Sci. Eng."},{"key":"10.1016\/j.addr.2025.115678_b0835","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jconrel.2006.02.015","article-title":"Elevated temperature accelerated release testing of PLGA microspheres","volume":"112","author":"Zolnik","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115678_b0840","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1208\/ps040205","article-title":"Assuring quality and performance of sustained and controlled release parenterals: workshop report","volume":"4","author":"Burgess","year":"2002","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.addr.2025.115678_b0845","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.2042-7158.2012.01482.x","article-title":"Accelerated in-vitro release testing methods for extended-release parenteral dosage forms","volume":"64","author":"Shen","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.addr.2025.115678_b0850","doi-asserted-by":"crossref","unstructured":"M. Merciadez, L. Alquier, R. Mehta, A. Patel, A. Wang, A Novel Method for the Elution of Sirolimus (Rapamycin) in Drug-Eluting Stents, Dissolution Technol. 18 (2011) 37\u201342. 10.14227\/DT180411P37.","DOI":"10.14227\/DT180411P37"},{"key":"10.1016\/j.addr.2025.115678_b0855","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jpha.2017.06.002","article-title":"Effect of nonionic surfactants in release media on accelerated in-vitro release profile of sirolimus eluting stents with biodegradable polymeric coating","volume":"8","author":"Raval","year":"2018","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.addr.2025.115678_b0860","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejps.2009.02.009","article-title":"A novel accelerated in vitro release method for biodegradable coating of drug eluting stents: Insight to the drug release mechanisms","volume":"37","author":"Kamberi","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.addr.2025.115678_b0865","doi-asserted-by":"crossref","first-page":"11604","DOI":"10.1039\/C4RA12524J","article-title":"Usage of different vessel models in a flow-through cell: in vitro study of a novel coated balloon catheter","volume":"5","author":"Bandomir","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.addr.2025.115678_b0870","first-page":"54D","article-title":"Maximal blood flow velocity in severe coronary stenoses measured with a Doppler guidewire","volume":"71","author":"Di Mario","year":"1993","journal-title":"Limitations for the Application of the Continuity Equation in the Assessment of Stenosis Severity, Am J Cardiol"},{"key":"10.1016\/j.addr.2025.115678_b0875","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2214\/AJR.19.21280","article-title":"Doppler Flow Measurement of lower Extremity arteries Adjusted by Pulsatility Index","volume":"214","author":"Liang","year":"2020","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.addr.2025.115678_b0880","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/S0741-5214(03)00706-7","article-title":"Magnetic resonance imaging measurement of blood volume flow in peripheral arteries in healthy subjects","volume":"38","author":"Klein","year":"2003","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.addr.2025.115678_b0885","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10618","article-title":"Design and use of an ex vivo peripheral simulating bioreactor system for pharmacokinetic analysis of a drug coated stent","volume":"9","author":"Chen","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.addr.2025.115678_b0890","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jvir.2010.12.027","article-title":"Polymer-free paclitaxel-coated Zilver PTX Stents\u2013evaluation of pharmacokinetics and comparative safety in porcine arteries","volume":"22","author":"Dake","year":"2011","journal-title":"J. Vasc. Interv. Radiol."},{"key":"10.1016\/j.addr.2025.115678_b0895","doi-asserted-by":"crossref","DOI":"10.3389\/fmedt.2021.675188","article-title":"The Development of an ex vivo Flow System to Assess Acute Arterial Drug Retention of Cardiovascular Intravascular Devices","volume":"3","author":"Cooper","year":"2021","journal-title":"Front. Med. Technol."},{"key":"10.1016\/j.addr.2025.115678_b0900","first-page":"E247","article-title":"The SYNERGY biodegradable polymer everolimus eluting coronary stent: Porcine vascular compatibility and polymer safety study","volume":"86","author":"Wilson","year":"2015","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"10.1016\/j.addr.2025.115678_b0905","first-page":"728","volume":"9","author":"Gogas","year":"2016","journal-title":"Ex Vivo Assessment, and Gene Analysis at the Stented\/scaffolded Segments and the Proximal and Distal Edges, JACC: Cardiovascular Interventions"},{"key":"10.1016\/j.addr.2025.115678_b0910","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jddst.2018.08.026","article-title":"In vitro release study of sirolimus from a PDLLA matrix on a bioresorbable drug-eluting stent","volume":"48","author":"Li","year":"2018","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.addr.2025.115678_b0915","doi-asserted-by":"crossref","DOI":"10.1115\/1.4023414","article-title":"Development and Evaluation of Drug Eluting Stent having Biphasic Release from a Single Layer of Biodegradable Polymer","volume":"7","author":"Thakkar","year":"2013","journal-title":"J. Med. Devices"},{"key":"10.1016\/j.addr.2025.115678_b0920","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1016\/j.biomaterials.2010.01.147","article-title":"In vitro and in vivo performance of a dual drug-eluting stent (DDES)","volume":"31","author":"Huang","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2025.115678_b0925","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10439-015-1456-7","article-title":"Modelling the Impact of Atherosclerosis on Drug Release and distribution from Coronary Stents","volume":"44","author":"McKittrick","year":"2016","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.addr.2025.115678_b0930","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jddst.2016.05.006","article-title":"Stability testing of drug eluting stents","volume":"35","author":"Kamberi","year":"2016","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.addr.2025.115678_b0935","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1159779","article-title":"A novel glycyrrhizin acid-coated stent reduces neointimal formation in a rabbit iliac artery model","volume":"14","author":"Teng","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2025.115678_b0940","article-title":"Resolute\u00ae and xience V\u00ae polymer\u2010based drug\u2010eluting stents compared in an atherosclerotic rabbit double injury model","volume":"81","author":"Van Dyck","year":"2013","journal-title":"Cathet Cardio Intervent"},{"key":"10.1016\/j.addr.2025.115678_b0945","unstructured":"P. Saami K. Yazdani, Preclinical Evaluation of Second-Generation Everolimus- and Zotarolimus-Eluting Coronary Stents, Journal of Invasive Cardiology 25 (2013). https:\/\/www.hmpgloballearningnetwork.com\/site\/jic\/articles\/preclinical-evaluation-second-generation-everolimus-and-zotarolimus-eluting-coronary-stents (accessed April 1, 2024)."},{"key":"10.1016\/j.addr.2025.115678_b0950","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.3390\/polym12081741","article-title":"Vascular Stents Coated with Electrospun Drug-Eluting Material: Functioning in Rabbit Iliac Artery","volume":"12","author":"Kuznetsov","year":"2020","journal-title":"Polymers"},{"key":"10.1016\/j.addr.2025.115678_b0955","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.jconrel.2012.07.004","article-title":"Enhanced drug delivery capabilities from stents coated with absorbable polymer and crystalline drug","volume":"162","author":"Carlyle","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115678_b0960","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s10856-009-3705-5","article-title":"In vitro and in vivo evaluation of the safety and stability of the TAXUS Paclitaxel-Eluting Coronary Stent","volume":"20","author":"Boden","year":"2009","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.addr.2025.115678_b0965","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/hrt.2005.061622","article-title":"Drug eluting stents: an updated meta-analysis of randomised controlled trials","volume":"92","author":"Roiron","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.addr.2025.115678_b0970","doi-asserted-by":"crossref","first-page":"3M","DOI":"10.1016\/j.amjcard.2007.08.016","article-title":"Design criteria for the ideal drug-eluting stent","volume":"100","author":"Ako","year":"2007","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.addr.2025.115678_b0975","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/cvr\/cvt115","article-title":"Biological responses in stented arteries","volume":"99","author":"Chaabane","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.addr.2025.115678_b0980","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.jacc.2009.01.050","article-title":"Five-Year Follow-up after Sirolimus-Eluting Stent Implantation","volume":"53","author":"Weisz","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2025.115678_b0985","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S1885-5857(09)60027-X","article-title":"Treatment of Paclitaxel-Eluting Stent Restenosis with Sirolimus-Eluting Stent Implantation\u2014Angiographic and Clinical Outcomes","volume":"61","author":"Byrne","year":"2008","journal-title":"Revista Espa\u00f1ola De Cardiolog\u00eda (english Edition)"},{"key":"10.1016\/j.addr.2025.115678_b0990","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/S0735-1097(01)01207-4","article-title":"null null, continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial","volume":"37","author":"Kiemeneij","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.addr.2025.115678_b0995","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.carrev.2017.05.013","article-title":"In-stent restenosis nine years after initial placement of a drug-eluting stent","volume":"19","author":"Hopkinson","year":"2018","journal-title":"Cardiovasc. Revasc. Med."},{"key":"10.1016\/j.addr.2025.115678_b1000","unstructured":"E. Sleiman, R. Tabet, B. Karam, D. Ayad, R. Royzman, Extremely Late In-Stent Thrombosis 12 Years After Implantation of a Drug-Eluting Stent, Cureus 12 (n.d.) e9053. 10.7759\/cureus.9053."},{"key":"10.1016\/j.addr.2025.115678_b1005","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4068\/cmj.2011.47.2.124","article-title":"A Case of Stent Thrombosis Occurred at 5 Years after Sirolimus-Eluting Stent Implantation","volume":"47","author":"Kim","year":"2011","journal-title":"Chonnam Med. J."},{"key":"10.1016\/j.addr.2025.115678_b1010","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114857","article-title":"Long-acting PLGA microspheres: advances in excipient and product analysis toward improved product understanding","volume":"198","author":"Wan","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2025.115678_b1015","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1208\/s12249-014-0177-9","article-title":"Nanomedicine Scale-up Technologies: Feasibilities and challenges","volume":"15","author":"Paliwal","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.addr.2025.115678_b1020","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1016\/j.apsb.2022.02.025","article-title":"Current approaches of nanomedicines in the market and various stage of clinical translation","volume":"12","author":"Shan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2025.115678_b1025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40005-019-00453-z","article-title":"Poly(lactic acid)\/poly(lactic-co-glycolic acid)-based microparticles: an overview","volume":"49","author":"Blasi","year":"2019","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.addr.2025.115678_b1030","unstructured":"Drug Eluting Stent Market Size, Share & Trends Report update 2030, (n.d.). https:\/\/www.grandviewresearch.com\/industry-analysis\/drug-eluting-stent-market (accessed May 6, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b1035","doi-asserted-by":"crossref","unstructured":"J. Vasc. Interv. Radiol. 34 (2023) 1929\u20131937. 10.1016\/j.jvir.2023.07.023.","DOI":"10.1016\/j.jvir.2023.07.023"},{"key":"10.1016\/j.addr.2025.115678_b1040","unstructured":"C. for D. and R. Health, Stellarex 0.035\u201d OTW Drug-coated Angioplasty Balloon \u2013 P160049\/S015, FDA (2022). https:\/\/www.fda.gov\/medical-devices\/recently-approved-devices\/stellarex-0035-otw-drug-coated-angioplasty-balloon-p160049s015 (accessed June 18, 2024)."},{"key":"10.1016\/j.addr.2025.115678_b1045","first-page":"497","article-title":"Stellarex drug\u2010coated balloon for treatment of femoropopliteal arterial disease\u2014The ILLUMENATE Global Study: 12\u2010Month results from a prospective, multicenter, single\u2010arm study","volume":"91","author":"Schro\u00eb","year":"2018","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"10.1016\/j.addr.2025.115678_b1050","unstructured":"Intravascular Lithotripsy System, (n.d.). https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf20\/P200039B.pdf (accessed June 18, 2024)."},{"key":"10.1016\/j.addr.2025.115678_b1055","unstructured":"Shockwave Medical-IVL Overview And MOA, (2024). https:\/\/shockwavemedical.com\/ivl-overview\/ (accessed May 6, 2025)."},{"key":"10.1016\/j.addr.2025.115678_b1060","unstructured":"Classificationg1.pdf, (n.d.). https:\/\/cdsco.gov.in\/opencms\/export\/sites\/CDSCO_WEB\/Pdf-documents\/medical-device\/Classificationg1.pdf (accessed May 15, 2024)."},{"key":"10.1016\/j.addr.2025.115678_b1065","unstructured":"Guidance for Medical Devices:Indian Pharmacopoeia Commission, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b1070","unstructured":"The Medical Devices Rules: 2017-Central Drugs Standard Control Organization, Ministry of Health and Family Welfare, Govt. of India, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b1075","unstructured":"Clinical Evaluation of Coronary Stents:Eurpean Commission, (n.d.)."},{"key":"10.1016\/j.addr.2025.115678_b1080","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00270-014-0904-3","article-title":"Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease","volume":"37","author":"Fanelli","year":"2014","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.addr.2025.115678_b1085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijcard.2017.01.054","article-title":"Calcium: a predictor of interventional treatment failure across all fields of cardiovascular medicine","volume":"231","author":"Mattesini","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.addr.2025.115678_b1090","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1540-8183.2010.00567.x","article-title":"Stent fracture in the coronary and peripheral arteries","volume":"23","author":"Adlakha","year":"2010","journal-title":"J. Interv. Cardiol."},{"key":"10.1016\/j.addr.2025.115678_b1095","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.avsg.2017.08.043","article-title":"Impact of Vascular Calcifications on Long Femoropopliteal Stenting Outcomes","volume":"47","author":"Kaladji","year":"2018","journal-title":"Ann. Vasc. Surg."},{"key":"10.1016\/j.addr.2025.115678_b1100","year":"2025","journal-title":"(n.d.)"},{"key":"10.1016\/j.addr.2025.115678_b1105","unstructured":"C. for D. and R. Health, Ethylene Oxide Sterilization Facility Updates, FDA (2021). https:\/\/www.fda.gov\/medical-devices\/general-hospital-devices-and-supplies\/ethylene-oxide-sterilization-facility-updates (accessed May 6, 2025)."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25001632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25001632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:57:32Z","timestamp":1772830652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X25001632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":221,"alternative-id":["S0169409X25001632"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2025.115678","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug delivery, development, and technological aspects for peripheral drug eluting stents","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2025.115678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115678"}}